Payment overview · 2025
General Payments
$175.53
9 reported records · 5 companies
Healthcare provider profile · identity verified
John P Agent, DO
Allopathic & Osteopathic Physicians|Internal Medicine · SALLISAW, OK · NPI 1649217191
Verified facts
What the public records show
CMS Open Payments records show John P Agent, DO received $175.53 in general payments during 2025 across 9 reported records.
Novo Nordisk Inc accounted for 33.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $58.81 | 33.5% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $53.00 | 30.2% | 3 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $27.40 | 15.6% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $21.73 | 12.4% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $14.59 | 8.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $175.53 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $38.74 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $37.06 | 2 | 2025 |
Source payment records
|
|||||
| STRENSIQ Normalized: strensiq |
Biological | Alexion Pharmaceuticals, Inc. | $27.40 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $21.73 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $20.07 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $19.47 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $15.94 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.59 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 116 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
41 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
116 | 30 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 763 | 242 |
| Levothyroxine Sodium | Levothyroxine Sodium | 608 | 181 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 482 | 164 |
| Gabapentin | Gabapentin | 478 | 118 |
| Tramadol Hcl | Tramadol Hcl | 421 | 94 |
| Amlodipine Besylate | Amlodipine Besylate | 397 | 138 |
| Omeprazole | Omeprazole | 378 | 116 |
| Lisinopril | Lisinopril | 338 | 117 |
| Metformin Hcl | Metformin Hcl | 332 | 113 |
| Tamsulosin Hcl | Tamsulosin Hcl | 327 | 99 |
| Alprazolam | Alprazolam | 315 | 62 |
| Metoprolol Succinate | Metoprolol Succinate | 288 | 95 |
| Furosemide | Furosemide | 252 | 85 |
| Pantoprazole Sodium | Pantoprazole Sodium | 250 | 82 |
| Potassium Chloride | Potassium Chloride | 249 | 98 |
| Carvedilol | Carvedilol | 242 | 79 |
| Duloxetine Hcl | Duloxetine Hcl | 231 | 72 |
| Losartan Potassium | Losartan Potassium | 223 | 80 |
| Zolpidem Tartrate | Zolpidem Tartrate | 221 | 40 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 201 | 63 |
| Allopurinol | Allopurinol | 199 | 53 |
| Trazodone Hcl | Trazodone Hcl | 186 | 61 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 178 | 53 |
| Metoprolol Tartrate | Metoprolol Tartrate | 169 | 45 |
| Glimepiride | Glimepiride | 160 | 53 |
| Pregabalin | Pregabalin | 158 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 146 | 43 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 141 | 48 |
| Eliquis | Apixaban | 139 | 39 |
| Clonazepam | Clonazepam | 131 | 31 |
| Finasteride | Finasteride | 128 | 41 |
| Tizanidine Hcl | Tizanidine Hcl | 128 | 55 |
| Sertraline Hcl | Sertraline Hcl | 123 | 39 |
| Clopidogrel | Clopidogrel Bisulfate | 119 | 40 |
| Montelukast Sodium | Montelukast Sodium | 118 | 40 |
| Ozempic | Semaglutide | 116 | 30 |
| Mounjaro | Tirzepatide | 113 | 28 |
| Temazepam | Temazepam | 112 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 110 | 40 |
| Hydrochlorothiazide | Hydrochlorothiazide | 105 | 34 |
| Irbesartan | Irbesartan | 102 | 35 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 98 | 23 |
| Meloxicam | Meloxicam | 93 | 28 |
| Simvastatin | Simvastatin | 93 | 26 |
| Lorazepam | Lorazepam | 91 | 25 |
| Jardiance | Empagliflozin | 90 | 22 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 86 | 28 |
| Doxycycline Hyclate | Doxycycline Hyclate | 76 | 63 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 76 | 18 |
| Baclofen | Baclofen | 71 | 18 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 68 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 68 | 23 |
| Celecoxib | Celecoxib | 67 | 18 |
| Eszopiclone | Eszopiclone | 67 | suppressed |
| Famotidine | Famotidine | 66 | 19 |
| Pioglitazone Hcl | Pioglitazone Hcl | 66 | 23 |
| Promethazine Hcl | Promethazine Hcl | 66 | 17 |
| Prednisone | Prednisone | 63 | 31 |
| Buspirone Hcl | Buspirone Hcl | 61 | 16 |
| Methylprednisolone | Methylprednisolone | 61 | 50 |
| Spironolactone | Spironolactone | 60 | 20 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 59 | 17 |
| Ezetimibe | Ezetimibe | 57 | 22 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 56 | 15 |
| Mirtazapine | Mirtazapine | 55 | 17 |
| Xarelto | Rivaroxaban | 54 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 53 | 16 |
| Azithromycin | Azithromycin | 52 | 46 |
| Testosterone Cypionate | Testosterone Cypionate | 52 | 15 |
| Alendronate Sodium | Alendronate Sodium | 50 | 17 |
| Cefdinir | Cefdinir | 50 | 44 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 48 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 48 | 36 |
| Paroxetine Hcl | Paroxetine Hcl | 48 | suppressed |
| Synthroid | Levothyroxine Sodium | 48 | 15 |
| Zaleplon | Zaleplon | 48 | 17 |
| Methocarbamol | Methocarbamol | 47 | 11 |
| Warfarin Sodium | Warfarin Sodium | 47 | 13 |
| Diazepam | Diazepam | 46 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 46 | 15 |
| Metformin Hcl Er | Metformin Hcl | 46 | 20 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 45 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 45 | 16 |
| Mupirocin | Mupirocin | 45 | 25 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 45 | 15 |
| Sumatriptan Succinate | Sumatriptan Succinate | 45 | 11 |
| Memantine Hcl | Memantine Hcl | 44 | 15 |
| Topiramate | Topiramate | 44 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 44 | 12 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 43 | 24 |
| Quetiapine Fumarate | Quetiapine Fumarate | 43 | 15 |
| Sulindac | Sulindac | 43 | 14 |
| Torsemide | Torsemide | 43 | 16 |
| Doxazosin Mesylate | Doxazosin Mesylate | 42 | 13 |
| Felodipine Er | Felodipine | 42 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 42 | 19 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 41 | 11 |
| Farxiga | Dapagliflozin Propanediol | 41 | 11 |
| Nitroglycerin | Nitroglycerin | 41 | 24 |
| Atenolol | Atenolol | 40 | 15 |
| Bupropion Xl | Bupropion Hcl | 40 | suppressed |
| Estradiol | Estradiol | 40 | 12 |
| Donepezil Hcl | Donepezil Hcl | 39 | 14 |
| Levetiracetam | Levetiracetam | 38 | suppressed |
| Fenofibrate | Fenofibrate | 37 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 37 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 35 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 35 | suppressed |
| Amoxicillin | Amoxicillin | 34 | 29 |
| Nifedipine Er | Nifedipine | 34 | suppressed |
| Trulicity | Dulaglutide | 34 | suppressed |
| Lovastatin | Lovastatin | 33 | suppressed |
| Myrbetriq | Mirabegron | 33 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 33 | 11 |
| Terazosin Hcl | Terazosin Hcl | 32 | suppressed |
| Ibuprofen | Ibuprofen | 31 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 31 | suppressed |
| Glipizide | Glipizide | 30 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 30 | suppressed |
| Glipizide Er | Glipizide | 29 | 13 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 29 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 28 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 28 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 28 | suppressed |
| Nabumetone | Nabumetone | 28 | suppressed |
| Ondansetron Odt | Ondansetron | 28 | 11 |
| Lacosamide | Lacosamide | 27 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 25 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 25 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 25 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 24 | suppressed |
| Sucralfate | Sucralfate | 24 | 11 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 23 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Entresto | Sacubitril/Valsartan | 23 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 23 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 22 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 22 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 22 | suppressed |
| Digoxin | Digoxin | 21 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 21 | suppressed |
| Nystatin | Nystatin | 21 | 14 |
| Trintellix | Vortioxetine Hydrobromide | 21 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 20 | suppressed |
| Fluconazole | Fluconazole | 20 | 16 |
| Ipratropium Bromide | Ipratropium Bromide | 20 | suppressed |
| Lactulose | Lactulose | 20 | suppressed |
| Lansoprazole | Lansoprazole | 20 | suppressed |
| Ramipril | Ramipril | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 19 | suppressed |
| Belsomra | Suvorexant | 19 | suppressed |
| Roflumilast | Roflumilast | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 15 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 17 | suppressed |
| Modafinil | Modafinil | 17 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 17 | 11 |
| Valsartan | Valsartan | 17 | suppressed |
| Methotrexate | Methotrexate Sodium | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 15 | suppressed |
| Levofloxacin | Levofloxacin | 15 | 15 |
| Acyclovir | Acyclovir | 14 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 14 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 14 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 13 | suppressed |
| Clotrimazole | Clotrimazole | 13 | suppressed |
| Klor-Con M20 | Potassium Chloride | 13 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Edarbi | Azilsartan Medoxomil | 12 | suppressed |
| Gemtesa | Vibegron | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Zonisamide | Zonisamide | 12 | suppressed |
| Anastrozole | Anastrozole | 11 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Etodolac | Etodolac | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $175.53 · 9 records | Novo Nordisk Inc | AIRSUPRA, BREZTRI, Dexcom G6 Transmitter, Ozempic, Rybelsus, STRENSIQ, Wegovy, XIFAXAN | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error